Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy (NCT05642611)
Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel or docetaxel, can cause a nerve disorder called peripheral neuropathy, which can cause numbness, tingling, or pain in the arms and legs. The 3 study approaches will use a device, called the Paxman Limb Cryocompression System, made of wraps that cool and/or compress the arms and legs. This study may help researchers determine if any of the study approaches are able to prevent taxane chemotherapy from causing peripheral neuropathy.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
- Biospecimen Collection (PROCEDURE)
- Cryocompression Therapy (PROCEDURE)
- Pneumatic Compression Therapy (PROCEDURE)
- Pneumatic Compression Therapy (PROCEDURE)
- Quality-of-Life Assessment (OTHER)
- Questionnaire Administration (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Contra Costa Regional Medical Center — Martinez, California
- Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
- Yale University — New Haven, Connecticut
- Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Kapiolani Medical Center for Women and Children — Honolulu, Hawaii
- University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
- Baptist Health Lexington — Lexington, Kentucky
- Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
- Henry Ford Hospital — Detroit, Michigan
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
- The Valley Hospital - Luckow Pavilion — Paramus, New Jersey
- Valley Health System Ridgewood Campus — Ridgewood, New Jersey
- University of New Mexico Cancer Center — Albuquerque, New Mexico
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- State University of New York Upstate Medical University — Syracuse, New York
- CaroMont Regional Medical Center — Gastonia, North Carolina
- Cone Health Cancer Center — Greensboro, North Carolina
- Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
- Rhode Island Hospital — Providence, Rhode Island
📞 Contact the Study Coordinator
Phone: (210) 614-8808
Email: jtrevino@swog.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Malignant Solid Neoplasm
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) — Philadelphia, Pennsylvania
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors — Birmingham, Alabama
- Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) — Philadelphia, Pennsylvania
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial — Birmingham, Alabama
- Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial — Bethesda, Maryland
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) — Philadelphia, Pennsylvania
Explore by condition: All Malignant Solid Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.